Insights

Gathering insights about XOR…

Similar companies to XOR

XOR Tech Stack

Media & News

XORTX Announces Presentation at the Rare and Genetic Disease Summit
CALGARY, Alberta, Dec. 12, 2024 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, is pleased to announce a presentation by Dr. Allen Davidoff at the Rare and Genetic Kidney Disease Summit, in Boston, Massachusetts at 10:30 am ET, Thursday December 12, 2024. The presentation entitled “Autosomal Dominant Polycystic Kidney Disease - Genetic and Environmental Factors → Evidence for Aberrant Purine Metabolism as a Second Hit Determining Disease Progression.”
Dec 12, 2024 | www.globenewswire.com
XORTX Announces Closing of US$1.5 Million Registered Direct Offering and Concurrent Private Placement
CALGARY, Alberta, Oct. 18, 2024 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, today announced that it has closed its registered direct offering and concurrent private placement, announced on October 17, 2024, for the purchase and sale of 810,810 common shares (or pre-funded warrants in lieu thereof) in a registered direct offering and common warrants to purchase up to 810,810 common shares in a concurrent private placement (together with the registered direct offering, the “Offering”) at a combined purchase price of US$1.85 per common share. The common warrants issued pursuant to the concurrent private placement have an exercise price of US$2.18, are immediately exercisable and expire five years from issuance.
Oct 18, 2024 | www.globenewswire.com
XORTX Initiates Precision Medicine Program
Pioneering Research Indicating a Role for Genetic Regulation of Xanthine Oxidase and Therapeutic Targeting of Aberrant Purine Metabolism Pioneering Research Indicating a Role for Genetic Regulation of Xanthine Oxidase and Therapeutic Targeting of Aberrant Purine Metabolism
Oct 09, 2024 | www.globenewswire.com
XORTX Announces Results of Annual and Special Meeting of Shareholders
CALGARY, Alberta, Sept. 13, 2024 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, is pleased to announce the results of its annual and special meeting of shareholders (the “Meeting”) held Thursday, September 12, 2024.
Sep 13, 2024 | www.globenewswire.com
XORTX Announces Re-filing of YE 2023 and Q2 2024 MD&A
CALGARY, Alberta, Sept. 12, 2024 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, announces that it has refiled its management's discussion and analysis (“MD&A”) for the financial year ended December 31, 2023 and for the interim period ended June 30, 2024 as a result of a continuous disclosure review by the Alberta Securities Commission.
Sep 12, 2024 | www.globenewswire.com
XORTX Reminds Shareholders of Voting Deadline for Upcoming Annual and Special Meeting of Shareholders
CALGARY, Alberta, Sept. 06, 2024 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, reminds shareholders of the upcoming deadline to vote at the Company's Annual General and Special Meeting (the "Meeting"), which is scheduled to be held on September 12, 2024.
Sep 06, 2024 | www.globenewswire.com
Independent Proxy Advisory Firm ISS Recommends XORTX Shareholders Vote FOR ALL Proposed Items at the Upcoming Annual and Special Meeting of Shareholders
CALGARY, Alberta, Sept. 03, 2024 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, is pleased to announce that leading independent proxy advisory firm Institutional Shareholder Services Inc. (“ISS”) has recommended Shareholders vote “FOR” all the proposed resolutions at the upcoming Annual and Special Meeting of Shareholders (the “Meeting”) to be held on September 12, 2024.
Sep 03, 2024 | www.globenewswire.com

XOR's Email Address Formats

XOR uses at least 1 format(s):

XOR Email Formats	Example	Percentage
FirstL@xor-t.com	JohnD@xor-t.com	31%
Last@xor-t.com	Doe@xor-t.com	28%
First@xor-t.com	John@xor-t.com	10%
FirstL@xor-t.com	JohnD@xor-t.com	31%

Frequently Asked Questions

Where is XOR's headquarters located?

XOR's main headquarters is located at Ben Gurion 18, P.O. Box 222 Givat-Shmual, Givat-Shmual 54101 Israel. The company has employees across 4 continents, including EuropeAsiaNorth America.

What is XOR's stock symbol?

XOR is a publicly traded company; the company's stock symbol is XRTX.

What is XOR's official website and social media links?

XOR's official website is xor-t.com and has social profiles on LinkedIn.

What is XOR's NAICS code?

XOR's NAICS code is 5415 - Computer Systems Design and Related Services.

How many employees does XOR have currently?

As of December 2024, XOR has approximately 51 employees across 4 continents, including EuropeAsiaNorth America. Key team members include Sales Manager: N. B. E.Bsm Group Manager: V. R.Senior Consultant: I. P. M.. Explore XOR's employee directory with LeadIQ.

What industry does XOR belong to?

XOR operates in the IT Services and IT Consulting industry.

What is XOR's email format?

XOR's email format typically follows the pattern of . Find more XOR email formats with LeadIQ.

XOR

IT Services and IT ConsultingGivat-Shmual, Israel51-200 Employees

Xor Technologies is a leading software infrastructure solutions provider. Winner of IBM beacon award - Best Tivoli solution, HP OpenView partner of the year, BMC Patrol/In-control, SUN IAM and CA Unicenter excellence awards, Xor Technologies established itself as a market leader of ESM and security solutions. Xor's main focus is in the following fields: Management solutions Security solutions Xor's is headquartered are in Givat-Shmual, Israel.

Company Overview

Headquarters: Ben Gurion 18, P.O. Box 222 Givat-Shmual, Givat-Shmual 54101 Israel
Website: xor-t.com
Stock Symbol: XRTX
NAICS Code: 5415 - Computer Systems Design and Related Services
Employees: 51-200